The US Food and Drug Administration (FDA) has approved Medtronic's Professional continuous glucose monitoring (CGM) system - iPro 2.
iPro2 is a three day evaluation setup procedure, where a glucose sensor is inserted into the patient’s skin and is connected to the sensor.
After three days of wear, the patient returns iPro2 where it is uploaded to new web-based CareLink iPro software which provides a summary of glucose data in easy-to-read reports.
iPro2 results provide healthcare providers insight into how diet, daily activities and medication affect their glucose levels.
The system can be used to identify nocturnal hypoglycemia or hyperglycemia following meals, providing an opportunity to make therapy adjustments that can result in better glucose control.